Double-blind controlled study on the effects of dietary diacylglycerol on postprandial serum and chylomicron triacylglycerol responses in healthy humans.
OBJECTIVE
The effects of dietary diacylglycerol (DG) on postprandial lipemia in healthy humans were investigated.


METHODS
Forty normolipidemic male volunteers ingested fat emulsions containing either DG oil or triacylglycerol (TG) oil, at different doses: 10 g (n = 13), 20 g (n = 10) and 44 g (n = 17). Two test emulsions were given at seven-days intervals in random order. Fatty acid compositions of the test oils had been adjusted to be equal. Fasting and postprandial serum lipid concentrations in each group and plasma lipoprotein lipids in the 20 g-fat ingestion group were measured during the postprandial intervals.


RESULTS
When DG emulsion was ingested, serum TG concentrations were significantly lower (p < 0.05) in the late postprandial phase, i.e., 4 hours, 6 hours as compared to the TG emulsion. The magnitude of postprandial lipemia (the area bounded by the curve above the fasting concentration) after ingestion of 44 g-DG emulsion was significantly less than that of 44 g-TG emulsion (6.54 +/- 5.12 and 8.45 +/- 7.54 mmol x h/L, mean +/- SD, respectively). Chylomicron TG, cholesterol, and phospholipid concentrations at 4 hours after ingestion of DG emulsion were significantly lower (p < 0.05) than those after the ingestion of TG emulsion at the same time point. No marked differences were observed for VLDL, LDL and HDL lipids between the test emulsions.


CONCLUSIONS
In the usual range of fat intake (10-44 g), postprandial response after ingestion of DG emulsion was significantly less than that after ingestion of TG emulsion in healthy human subjects.
Taguchi
H
H
Biological Science Laboratories, Kao Corporation, Haga, Tochigi, Japan. 304468@kastanet.kao.co.jp
Watanabe
H
H
Onizawa
K
K
Nagao
T
T
Gotoh
N
N
Yasukawa
T
T
Tsushima
R
R
Shimasaki
H
H
Itakura
H
H
D000328:Adult; D019540:Area Under Curve; D001786:Blood Glucose / Q000378:metabolism; D002914:Chylomicrons / Q000097:blood / Q000187:drug effects*; D003327:Coronary Disease / Q000517:prevention & control; D004042:Dietary Fats, Unsaturated / Q000494:pharmacology; D004075:Diglycerides / Q000493:pharmacokinetics / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004655:Emulsions; D006801:Humans; D007328:Insulin / Q000097:blood; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D019518:Postprandial Period; D014280:Triglycerides / Q000097:blood* / Q000493:pharmacokinetics / Q000494:pharmacology*
D001786:Blood Glucose; D002914:Chylomicrons; D004042:Dietary Fats, Unsaturated; D004075:Diglycerides; D004655:Emulsions; D007328:Insulin; D008055:Lipids; D008074:Lipoproteins; D014280:Triglycerides